glyco-conjugate neisseria meningitidis serogroup c vaccine

Vaccineexperimental

Clinical trial activity

11 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
9
Phase 3
6
Phase 4
2

Earliest trial started Mar 1, 2003 (NCT00801957)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • glyco-conjugate neisseria meningitidis serogroup c vaccine
  • meningitec

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01129518Phase 4Jun 1, 2010GlaxoSmithKline, University of Oxford
NCT00955682Phase 3Aug 1, 2009GlaxoSmithKline
NCT00891176Phase 3May 1, 2009GlaxoSmithKline
NCT00508261Phase 3Aug 1, 2007GlaxoSmithKline
NCT00474266Phase 3Jun 1, 2007GlaxoSmithKline
NCT00463437Phase 3Apr 1, 2007GlaxoSmithKline
NCT00322335Phase 3May 1, 2006GlaxoSmithKline
NCT00581035Phase 4Jan 1, 2006Pfizer, Wyeth
NCT00134719Phase 2Apr 1, 2005GlaxoSmithKline
NCT00801957Phase 2Mar 1, 2003Astellas
NCT00127855Phase 2Mar 1, 2003GlaxoSmithKline
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit9832003
AstellasFor profit1112003
PfizerFor profit1112006
University of OxfordAcademic/Hospital1112010
WyethFor profit1012006
5 organizations
Page 1 / 1